Among patients with type 2 diabetes who have or are at risk for gout, the use of sodium-glucose cotransporter type 2 inhibitors vs sulfonylurea was associated with a lower incidence of gout and ...
No increased risk of thrombotic events identified despite rise in erythrocytosis among sodium-glucose cotransporter 2 inhibitor (SGLT2i) users with type 2 diabetes, study finds. Although ...
The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback